Mirum Pharmaceuticals, Inc. (MIRM) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Mirum Pharmaceuticals, Inc. (MIRM) Bundle
Streamline your analysis and boost precision with our (MIRM) DCF Calculator! Equipped with real data from Mirum Pharmaceuticals and customizable assumptions, this tool empowers you to forecast, analyze, and value (MIRM) just like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | 19.1 | 77.1 | 186.4 | 279.6 | 419.3 | 629.0 | 943.5 | 1,415.3 |
| Revenue Growth, % | 0 | 0 | 0 | 302.66 | 141.85 | 50 | 50 | 50 | 50 | 50 |
| EBITDA | -52.2 | -102.3 | -65.4 | -122.4 | -136.5 | -40.9 | -61.4 | -92.1 | -138.2 | -207.3 |
| EBITDA, % | 100 | 100 | -341.66 | -158.85 | -73.23 | -14.65 | -14.65 | -14.65 | -14.65 | -14.65 |
| Depreciation | .3 | .6 | 1.0 | 3.7 | 10.8 | 120.6 | 180.9 | 271.3 | 407.0 | 610.5 |
| Depreciation, % | 100 | 100 | 5.09 | 4.78 | 5.81 | 43.14 | 43.14 | 43.14 | 43.14 | 43.14 |
| EBIT | -52.5 | -102.9 | -66.4 | -126.1 | -147.3 | -44.2 | -66.3 | -99.4 | -149.2 | -223.7 |
| EBIT, % | 100 | 100 | -346.75 | -163.62 | -79.04 | -15.81 | -15.81 | -15.81 | -15.81 | -15.81 |
| Total Cash | 140.0 | 231.8 | 156.5 | 251.7 | 286.3 | 279.6 | 419.3 | 629.0 | 943.5 | 1,415.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 3.3 | 24.0 | 68.0 | 159.2 | 238.8 | 358.1 | 537.2 | 805.8 |
| Account Receivables, % | 100 | 100 | 17.07 | 31.14 | 36.47 | 56.94 | 56.94 | 56.94 | 56.94 | 56.94 |
| Inventories | .0 | .0 | 1.5 | 5.6 | 22.3 | 127.0 | 190.5 | 285.7 | 428.5 | 642.8 |
| Inventories, % | 100 | 100 | 7.91 | 7.22 | 11.97 | 45.42 | 45.42 | 45.42 | 45.42 | 45.42 |
| Accounts Payable | 3.4 | 3.2 | 9.2 | 8.7 | 7.4 | 147.1 | 220.7 | 331.0 | 496.6 | 744.9 |
| Accounts Payable, % | 100 | 100 | 47.89 | 11.28 | 3.98 | 52.63 | 52.63 | 52.63 | 52.63 | 52.63 |
| Capital Expenditure | -.3 | -.2 | -19.0 | -.3 | -20.1 | -61.8 | -92.7 | -139.1 | -208.6 | -312.9 |
| Capital Expenditure, % | 100 | 100 | -99.4 | -0.36075 | -10.79 | -22.11 | -22.11 | -22.11 | -22.11 | -22.11 |
| Tax Rate, % | -0.61013 | -0.61013 | -0.61013 | -0.61013 | -0.61013 | -0.61013 | -0.61013 | -0.61013 | -0.61013 | -0.61013 |
| EBITAT | -52.6 | -102.9 | -66.4 | -120.4 | -148.2 | -43.8 | -65.7 | -98.5 | -147.8 | -221.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -49.2 | -102.7 | -83.2 | -142.3 | -219.5 | -41.2 | -47.0 | -70.5 | -105.8 | -158.7 |
| WACC, % | 9.16 | 9.16 | 9.16 | 9.13 | 9.16 | 9.16 | 9.16 | 9.16 | 9.16 | 9.16 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -308.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -162 | |||||||||
| Terminal Value | -2,263 | |||||||||
| Present Terminal Value | -1,460 | |||||||||
| Enterprise Value | -1,769 | |||||||||
| Net Debt | 22 | |||||||||
| Equity Value | -1,790 | |||||||||
| Diluted Shares Outstanding, MM | 41 | |||||||||
| Equity Value Per Share | -43.79 |
What You Will Receive
- Customizable Excel Template: A fully adaptable Excel-based DCF Calculator featuring pre-filled real MIRM financials.
- Actual Market Data: Historical performance data and forward-looking estimates (highlighted in the yellow cells).
- Adjustable Forecasts: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Instant Calculations: Quickly observe how your inputs affect Mirum Pharmaceuticals’ valuation.
- Professional Grade Tool: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Design: Organized for clarity and ease of use, complete with step-by-step guidance.
Key Features
- Customizable Clinical Parameters: Adjust essential inputs such as drug efficacy rates, development timelines, and market penetration.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and other financial metrics in real-time.
- High-Precision Analysis: Leverages Mirum Pharmaceuticals' actual financial data for accurate valuation results.
- Effortless Scenario Testing: Evaluate various assumptions and analyze outcomes with ease.
- Efficiency Booster: Streamlines the valuation process by removing the need for intricate model construction.
How It Works
- Download the Template: Gain immediate access to the Excel-based MIRM DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional factors.
- Instant Calculations: The model automatically recalculates Mirum Pharmaceuticals' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial decisions.
Why Choose This Calculator for Mirum Pharmaceuticals (MIRM)?
- User-Friendly Interface: Tailored for both novice and experienced users.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Witness immediate updates to Mirum’s valuation as you modify inputs.
- Preloaded Data: Comes with Mirum’s actual financial information for swift evaluations.
- Preferred by Experts: Utilized by financial analysts and investors for strategic decision-making.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for assessing Mirum Pharmaceuticals, Inc. (MIRM) investments.
- Pharmaceutical Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Offer clients precise valuation insights for Mirum Pharmaceuticals, Inc. (MIRM) stock.
- Students and Educators: Utilize real-world data to practice and teach financial modeling in the biotech sector.
- Biotech Enthusiasts: Gain insights into how biotech companies like Mirum Pharmaceuticals, Inc. (MIRM) are valued in the market.
What the Template Contains
- Preloaded MIRM Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.